Page last updated: 2024-07-31 15:46:46

5-amino-2,4,6-triiodoisophthalic acid

Description

5-amino-2,4,6-triiodoisophthalic acid: structure in first source [MeSH]

Cross-References

ID SourceID
PubMed CID3015783
SCHEMBL ID377437
MeSH IDM0459423

Synonyms (46)

Synonym
STL290529
5-amino-2,4,6-triiodoisophthalic acid, 95%
isophthalic acid, 5-amino-2,4,6-triiodo-
inchi=1/c8h4i3no4/c9-3-1(7(13)14)4(10)6(12)5(11)2(3)8(15)16/h12h2,(h,13,14)(h,15,16
5-amino-2,4,6-triiodobenzene-1,3-dicarboxylic acid
35453-19-1
5-amino-2,4,6-triiodoisophthalic acid
AKOS005287314
5-amino-2,4,6-triiodo-1,3-benzenedicarboxylic acid
unii-a17g990rt0
1,3-benzenedicarboxylic acid, 5-amino-2,4,6-triiodo-
einecs 252-575-4
a17g990rt0 ,
ec 252-575-4
c8h4i3no4
FT-0619972
AM20060610
4B9H
iohexol impurity k [ep impurity]
2,4,6-triiodo-5-aminoisophthalic acid
JEZJSNULLBSYHV-UHFFFAOYSA-N
MLS006011502
smr002528285
5-amino-2,4,6-triiodo-benzene-1,3-dicarboxylic acid
SCHEMBL377437
W-106670
5-amino-2,4,6-triiodoisophthalicacid
5-amino-2,4,6-iodoisophthalic acid
mfcd00190167
5-amino-2,4,6-triiodoisophthalic acid, analytical standard
DTXSID10188969
AC-8409
sr-01000944807
SR-01000944807-1
SY030125
'5-amino-2,4,6-triiodoisophthalic acid'
AS-12308
BCP13935
EN300-20717
BB 0310408
O11343
Q27273489
YSWG562
F6782-3693
CS-W022287
Z104480184

Bioassays (1)

Assay IDTitleYearJournalArticle
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2013eLife, Jul-02, Volume: 2ISSN: 2050-084XFungal effector Ecp6 outcompetes host immune receptor for chitin binding through intrachain LysM dimerization.

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (70.00)29.6817
2010's2 (20.00)24.3611
2020's1 (10.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
lactic acid2-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
2003200321.0low000100
endolysinalpha-amino acid;
diamino acid;
polar amino acid
Daphnia magna metabolite201920195.0low000010
nitratesmonovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species
2003200321.0low000100
thiosulfatesdivalent inorganic anion;
sulfur oxide;
sulfur oxoanion
human metabolite2003200321.0low000100
sulfitesdivalent inorganic anion;
sulfur oxide;
sulfur oxoanion
2003200321.0low000100
diatrizoic acidacetamides;
benzoic acids;
organoiodine compound
environmental contaminant;
radioopaque medium;
xenobiotic
2008200816.0low000100
iohexolbenzenedicarboxamide;
organoiodine compound
environmental contaminant;
radioopaque medium;
xenobiotic
2008200816.0low000100
iopromidedicarboxylic acid diamide;
organoiodine compound
environmental contaminant;
nephrotoxic agent;
radioopaque medium;
xenobiotic
2008200816.0low000100
thiamine pyrophosphateorganic chloride salt;
vitamin B1
2008200816.0low000100
4,4'-bipyridylbipyridine2008200915.5medium000200
iodinehalide anion;
monoatomic iodine
human metabolite2003200321.0low000100
phenyl acetatebenzenes;
phenyl acetates
2003200321.0low000100
transferrin2008200816.0low000100
5-aminoisophthalic acid2003200321.0medium000100
lithiumalkali metal atom202120213.0low000001
muramidase200820218.0medium000111
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Benign Neoplasms02008200816.0high000100
Neoplasms02008200816.0high000100